Impact of age and gender on risk of hepatocellular carcinoma after hepatitis B surface antigen seroclearance

Journal of Hepatology

Volumn 67, Issue 5, 2017, Pages 902-908

  Yip, Terry Cheuk Fung ^a   Chan, Henry Lik Yuen ^a   Wong, Vincent Wai Sun ^a   Tse, Yee Kit ^a   Lam, Kelvin Long Yan ^a   Wong, Grace Lai Hung ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Age; Antiviral therapy; Gender; HBsAg seroclearance; HBsAg seroreversion; HBV; HCC; Sustained response

Indexed keywords

ALANINE AMINOTRANSFERASE; BILIRUBIN; HEPATITIS B SURFACE ANTIGEN; INTERFERON; NUCLEOSIDE ANALOG; PEGINTERFERON; ANTIVIRUS AGENT;

ADULT; AGE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; BILIRUBIN BLOOD LEVEL; CANCER RISK; CHRONIC HEPATITIS B; COHORT ANALYSIS; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PLATELET COUNT; PREDICTIVE VALUE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS; SEX DIFFERENCE; COMPLICATION; HONG KONG; IMMUNOLOGY; INCIDENCE; LIVER TUMOR; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; RISK FACTOR; SEX FACTOR;

AGE FACTORS; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; FEMALE; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B, CHRONIC; HONG KONG; HUMANS; INCIDENCE; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; RISK FACTORS; SEX FACTORS;

EID: 85026823212     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2017.06.019     Document Type: Article

References (26)

1. Chan, S.L., Wong, V.W., Qin, S., Chan, H.L., Infection and cancer: the case of hepatitis B. J Clin Oncol 34 (2016), 83–90.
2. Chu, C.M., Liaw, Y.F., Hepatitis B surface antigen seroclearance during chronic HBV infection. Antivir Ther 15 (2010), 133–143.
3. Yip, T.C., Wong, V.W., Tse, Y.K., Chan, H.L., Wong, G.L., Hepatitis B surface antigen seroclearance in a cohort of 154,740 patients with chronic hepatitis B: a 15-year follow-up study. Hepatol Int, 11, 2017, S75.
4. Ahn, S.H., Park, Y.N., Park, J.Y., Chang, H.Y., Lee, J.M., Shin, J.E., et al. Long-term clinical and histological outcomes in patients with spontaneous hepatitis B surface antigen seroclearance. J Hepatol 42 (2005), 188–194.
5. Liu, J., Yang, H.I., Lee, M.H., Lu, S.N., Jen, C.L., Batrla-Utermann, R., et al. Spontaneous seroclearance of hepatitis B seromarkers and subsequent risk of hepatocellular carcinoma. Gut 63 (2014), 1648–1657.
6. Simonetti, J., Bulkow, L., McMahon, B.J., Homan, C., Snowball, M., Negus, S., et al. Clearance of hepatitis B surface antigen and risk of hepatocellular carcinoma in a cohort chronically infected with hepatitis B virus. Hepatology 51 (2010), 1531–1537.
7. Chen, Y.C., Sheen, I.S., Chu, C.M., Liaw, Y.F., Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection. Gastroenterology 123 (2002), 1084–1089.
8. Kim, G.A., Lim, Y.S., An, J., Lee, D., Shim, J.H., Kim, K.M., et al. HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability. Gut 63 (2014), 1325–1332.
9. Kim, G.A., Lee, H.C., Kim, M.J., Ha, Y., Park, E.J., An, J., et al. Incidence of hepatocellular carcinoma after HBsAg seroclearance in chronic hepatitis B patients: a need for surveillance. J Hepatol 62 (2015), 1092–1099.
10. Liu, F., Wang, X.W., Chen, L., Hu, P., Ren, H., Hu, H.D., Systematic review with meta-analysis: development of hepatocellular carcinoma in chronic hepatitis B patients with hepatitis B surface antigen seroclearance. Aliment Pharmacol Ther 43 (2016), 1253–1261.
11. Yang, H.I., Yuen, M.F., Chan, H.L., Han, K.H., Chen, P.J., Kim, D.Y., et al. Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. Lancet Oncol 12 (2011), 568–574.
12. Cheng MC, Tong YH, Kwok TC, Cheng IT, Chung AP, Leung JK, et al. Development Journey of Clinical Data Analysis and Reporting System (CDARS) in Hospital Authority of Hong Kong. MEDINFO. 2010:1468.
13. Wong, G.L., Chan, H.L., Chan, H.Y., Tse, P.C., Tse, Y.K., Mak, C.W., et al. Accuracy of risk scores for patients with chronic hepatitis B receiving entecavir treatment. Gastroenterology 144 (2013), 933–944.
14. Wong, V.W., Chan, S.L., Mo, F., Chan, T.C., Loong, H.H., Wong, G.L., et al. Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. J Clin Oncol 28 (2010), 1660–1665.
15. Trepo, C., Chan, H.L., Lok, A., Hepatitis B virus infection. Lancet 384 (2014), 2053–2063.
16. European Association For The Study Of The L. EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection. J Hepatol 57 (2012), 167–185.
17. Sarin, S.K., Kumar, M., Lau, G.K., Abbas, Z., Chan, H.L., Chen, C.J., et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int 10 (2016), 1–98.
18. Terrault, N.A., Bzowej, N.H., Chang, K.M., Hwang, J.P., Jonas, M.M., Murad, M.H., et al. AASLD guidelines for treatment of chronic hepatitis B. Hepatology 63 (2016), 261–283.
19. Levrero, M., Zucman-Rossi, J., Mechanisms of HBV-induced hepatocellular carcinoma. J Hepatol 64 (2016), S84–S101.
20. Bruix, J., Sherman, M., American Association for the Study of Liver D. Management of hepatocellular carcinoma: an update. Hepatology 53 (2011), 1020–1022.
21. European Association for the Study of the L, European Organisation for R, Treatment of C. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 56 (2012), 908–943.
22. Omata, M., Lesmana, L.A., Tateishi, R., Chen, P.J., Lin, S.M., Yoshida, H., et al. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int 4 (2010), 439–474.
23. Chan, H.L., Hui, A.Y., Wong, M.L., Tse, A.M., Hung, L.C., Wong, V.W., et al. Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma. Gut 53 (2004), 1494–1498.
24. Wong, G.L., Chan, H.L., Yiu, K.K., Lai, J.W., Chan, V.K., Cheung, K.K., et al. Meta-analysis: The association of hepatitis B virus genotypes and hepatocellular carcinoma. Aliment Pharmacol Ther 37 (2013), 517–526.
25. McGlynn, K.A., Sahasrabuddhe, V.V., Campbell, P.T., Graubard, B.I., Chen, J., Schwartz, L.M., et al. Reproductive factors, exogenous hormone use and risk of hepatocellular carcinoma among US women: results from the Liver Cancer Pooling Project. Br J Cancer 112 (2015), 1266–1272.
26. Li, S., Ho, S.C., Sham, A., Relationship between menopause status, attitude toward menopause, and quality of life in Chinese midlife women in Hong Kong. Menopause 23 (2016), 67–73.